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Background: This study compared the efficacy of ketorolac alone versus its combination with tramadol/acet-
aminophen for pain control after mandibular third molar surgery. 
Material and Methods: A randomized, triple-blind clinical trial was carried out with 52 patients divided into 2 
groups: Group K+T+A (1 tablet of Ketorolac 10 mg plus and 1 capsule of Tramadol 37.5 mg/acetaminophen 325 
mg) and Group K (1 tablet of Ketorolac 10 mg plus and 1 placebo capsule). The treatments were given 1 h before 
the surgery and was repeated 4 times per day, for 48 h. The difference in postoperative pain was assessed by 4 
primary end-points: pain intensity (VAS 100mm, for 48 h), rescue medication, overall assessment and adverse 
effects. 
Results: Significant differences in pain intensity were observed in the different times (p < 0.05). The comparison 
of groups in each time showed significant differences only of 9 h, with lower level of pain intensity for group 
K+T+A (p = 0.005). The need of analgesics was higher in Group K (p < 0.001), the need of antiemetic were greater 
in Group K+T+A (p < 0.0001). No significant difference between groups were observed in overall assessment. The 
adverse effects was higher in Group K+T+A. 
Conclusions: The current study showed that both ketorolac and the combination of ketorolac plus tramadol/acet-
aminophen showed good control of pain after the extraction of the lower third molars. Although the combination 
group showed lower pain at 9 h, the difference is small and not clinically relevant. 
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Introduction
Third molar surgery is often accompanied by postop-
erative complications such as pain, buccal swelling and 
trismus (1). Among these, pain is one of the most com-
mon and significant postoperative complications, and it 
mainly arise from inflammatory response (2). 
Several biochemical mediators are involved in the pain 
process, particularly histamine, bradykinin and prosta-
glandins (3). The intensity of postoperative pain ranges 
from moderate to severe during the first 24 h after sur-
gery, with the pain peak being within the first 12 h when 
a medium-acting local anesthetic is used (4).
Numerous studies have investigated alternatives for the 
management of pain and discomfort generated by third 
molar surgery (5). Several analgesics have been used for 
this purpose, including nonsteroidal anti-inflammatory 
drugs and some opioids (3).
Among the nonsteroidal anti-inflammatory drugs in-
vestigated, ketorolac is one of the pharmacological op-
tions available, it is reported to have a potent analgesic 
effect similar to opioids (6) as well as a moderate anti-
inflammatory activity (7), which seems adequate for the 
treatment of moderate-to-severe acute pain (8). Due to 
these characteristics, this drug has been investigated for 
pain control after third molar surgeries. 
Despite these promising findings, rescue medication for 
pain relief was still necessary, even with the adminis-
tration of ketorolac, which suggests that preoperative 
administration is not enough to eliminate postoperative 
pain (9,10).
Combining analgesics may provide greater analgesia 
than the individual agents through the synergistic ac-
tion of the individual drugs (11), and allowing the use 
of lower doses for each medication may improve the 
patients’ tolerability (9,11). However, among the several 
number of possible drug combinations, there is a lack 
of knowledge regarding which combination and the re-
spective drug dosages have a better analgesic efficacy 
(12).
Perhaps combining a nonsteroidal anti-inflammatory 
drug (NSAID) such as ketorolac with opioid analge-
sics such as tramadol/acetaminophen may lead to low-
er postoperative pain. Clinical studies have reported 
that the combination of tramadol/acetaminophen 37.5 
mg/325 mg was effective and well tolerated in patients 
with dental pain (13). 
Third molar surgery pain is an excellent clinical model 
for acute pain (4). Pain of this type is predictable, gener-
ally acute and of moderate-to-severe intensity. To the 
extent of the author’s knowledge, no randomized clini-
cal trial has compared the efficacy of ketorolac alone 
versus its combination with tramadol/acetaminophen 
administered orally to control pain intensity after third 
molar surgery, which was the aim of the present inves-
tigation.
Material and Methods 
This randomized controlled clinical trial was approved 
by the ethics committee of State University of Ponta 
Grossa, Ponta Grossa, Paraná, Brazil (≠ 1.449.613), 
registered in the Brazilian Registry of Clinical Trials 
(≠ RBR-3phy2q) and prepared using the protocol estab-
lished by the Consolidated Standards of Reporting Tri-
als Statement (14). 
All participants included in this study signed a free and 
informed consent form and underwent surgery during 
sessions that were part of the Clinic of Oral and Maxil-
lofacial Surgery in the Department of Oral and Maxillo-
facial Surgery and Dental Specialty Center of the State 
University of Ponta Grossa, Brazil. This study was per-
formed from March 8th, 2016, to December 14th, 2016, 
in the city of Ponta Grossa (Paraná, Brazil). 
Participants with classification of surgical risk ASA 1 
(American Society of Anesthesiologists) were selected, 
with indication of treatment for bilateral third-molar 
removal, in similar inclusion pattern. Orthopantomo-
grams were taken to ensure similarity of the tooth incli-
nations. Tooth inclinations were determined using the 
classifications provided by Winter, using only the verti-
cal and mesioangular positions. We included position 
“B” and class “II” relationship, which was based on the 
Pell and Gregory classification; with an extraction de-
gree of difficulty from mild to moderate and at least 1/3 
of the root formed, according to the radiographic evalu-
ation, ensuring a lower variability in surgical trauma 
during the extraction on both sides (right and left) in 
each patient selected.
Patients with a history of hypersensitivity to medica-
tions used in the study; pregnant women, asthmatics, 
diabetics, infants, hypertensives, patients with gastroin-
testinal disorders (ulcer and bleeding), myasthenia gra-
vis, glaucoma, patients who were immunosuppressed, 
dependent on narcotic drugs, who had neurological and/
or behavioral changes, users of anti-inflammatories or 
antihypertensive drugs were not included in the study. 
The study followed a crossover design, i.e., a single pa-
tient was submitted to two different pharmacological 
protocols for postoperative pain control. 
The participants in Group K+T+A – received 1 tablet of 
Ketorolac 10 mg (Toragesic®, EMS Farmacêutica, Hor-
tolândia, São Paulo, Brazil) plus 1 capsule of Tramadol 
37.5 mg/acetaminophen 325 mg (Amanda Pharmaceuti-
cal Manipulations®, Ponta Grossa, Paraná, Brazil) un-
der oral route 1 h before surgery and every 6 h for 48 
h. In Group K – received 1 tablet of Ketorolac 10 mg 
(Toragesic®) plus 1 placebo capsule (Amanda Pharma-
ceutical Manipulations®), under oral route 1 h before 
surgery and every 6 h for 48 h. 
Sample size calculation was done by the website www.
sealedenvelope.com, using the primary outcome pain 
intensity of postoperative pain. To determine if oral ke-
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torolac is as effective as its association with tramadol/
acetaminophen (considering an equivalence limit of 20 
units of the 0-100 visual analog scale (VAS); 90% power 
and type I error of 5%), this equivalence clinical trial re-
quired a minimum sample size of 46 participants, but 52 
healthy individuals were selected for this clinical trial.
The randomization of the groups was performed through 
the generation of a list that determined the group of the 
first surgery. This random order of surgeries was kept 
in opaque  and sealed envelopes, which were numbered 
sequentially. Immediately before the start of the first 
surgery, the side to be operated was determined by the 
coin toss. The envelope was opened to reveal the group, 
so the other side to be operated would receive treatment 
from the other group, one month after, respecting the 
washout period between treatments. To keep the op-
erator, evaluator and patient blind, all medicines, were 
placed in identical capsules, and encoded by an inde-
pendent investigator, not involved in the surgical and 
assessment steps. The surgeon and participant were not 
aware, at any time, of which drug was administered to 
the chosen side. Antibiotic prophylaxis with pre-admin-
istration of amoxicillin 1 g (Generic, Tetuo ® - Anápo-
lis, GO, Brazil) or clindamycin 600 mg (Generic, Tetuo 
® - Anápolis, GO, Brazil), in those participants allergic 
to amoxicillin,  was given orally 1 h prior to surgery.
The surgical procedure was performed according to the 
principles of third molar removal surgery, from asepsis 
to synthesis, using routine materials and instruments 
required for this surgical practice. The same surgical 
technique was performed on both sides. Anesthesia was 
performed through the regional block of the inferior 
alveolar, lingual and buccal nerve using the same an-
esthesia (mepivacaine 2% with epinephrine 1: 100.000 
- Mepiadre - Nova DFL®, Rio de Janeiro, RJ, Brazil). 
Two types of rescue medication were prescribed to be 
used if needed: 
1) tablets of acetaminophen 500 mg (Generic, Tetuo ® - 
Anápolis, GO, Brazil), with instructions to take 1 tablet 
of the drug in case of pain every 6 h; and 
2) tablets of ondansetron 4 mg (Vonau flash, Biolab®, 
Taboão da Serra, SP, Brazil), with instructions to take 
1 tablet of the drug in case of nausea. The participants 
were also asked to take notes (day and time) whenever 
consuming these drugs in an appropriate questionnaire 
form given by the surgeon after each surgery.
-Pain assessments
Analgesic efficacy was assessed based on four key end-
points, which the patients were required to record on a 
pain diary:
Pain intensity 
Participants were instructed to record their postopera-
tive pain intensity (immediately, 3, 6, 9, 12, 24 and 48 h 
after surgery) on a VAS 0 to 100 mm scale, where 0 = 
no pain and 100 = unbearable pain. 
Total number of rescue medication consumption 
Participants were also instructed to record the total 
amount of analgesics (acetaminophen 500 mg tablets) 
or antiemetic (ondansetron 4 mg) consumed during the 
evaluation period (48 h) in their form. 
Global assessment
Participants were asked to provide an overall evalua-
tion of the efficacy of the surgery regarding pain on a 
five-point categorical scale at the end of the trial. The 
categories of scale were 1 = poor, 2 = fair, 3 = good, 4 = 
very good and 5 = excellent, in which excellent means 
minimum pain and poor means severe pain (15).
Assessment of adverse effects 
Participants were asked to include the occurrence of 
some common side effects such as dizziness, nausea, 
vomiting, stomachaches or other gastrointestinal dis-
comforts, migraines or effects. The participants were 
also instructed to note any rarer occurrences such as 
prolonged bleeding after surgery, renal problems and/or 
other gastrointestinal disorders (9).
-Statistical analysis
The need for rescue medication (paracetamol and on-
dansetron) was analyzed by the McNemar’s test. The 
intensity of pain in each time period, the consumption 
of rescue medication and the evaluation of the over-
all effect for the two groups were performed with the 
Wilcoxon Signed-Rank test. Within each group, pain 
intensity at different periods was compared with the 
Friedman and Student Neuman’s tests. All tests were 
at a significance level of 0.05 with the software Sigma 
Plot Software program (Systat Software, San Jose, Cali-
fornia, USA).
Results
Three out of the 52 patients did not perform the second 
surgery due to postoperative complications in the first 
surgery. The patients were immediately treated, and the 
complications were controlled, but they did not want to 
do the second surgery. Two complications were related 
to the surgical procedure: paresthesia (Group K) and in-
fection (Group K+T+A). The other complication (Group 
K+T+A) occurred due to gastrointestinal symptoms (the 
patient had nausea and vomiting, she went to a hospital 
and, during treatment, she had an extrapyramidal re-
action due to metoclopramide). All patients recovered 
well from these adverse effects.
Baseline characteristics
A total of 52 patients were selected (Fig. 1). The overall 
mean age was 20.8 ± 3.2 years  (ranging from 18 and 
35 years), 77% were women, 5.7% were smokers, the 
overall mean weight was 59.8 ± 9.8, the overall  mean 
height was 166.8 ± 7.9 and 100% were white. Significant 
differences were observed among the different time 
assessments (p < 0.05; Table 1). The level of pain in-
creased after surgery, reaching a peak after 3 h for both 
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Fig. 1. Flow diagram of the clinical trials including detailed information on the excluded participants.
Time assessment Median (interquartile range) Group K+T+A vs. Group K
p-value*Group K+T+A Group K
After surgery 0 (0 – 0) A** 0 (0 – 0) a** 0.50
3 h 9 (0 – 16) B 11.5 (2 – 20.2) b 0.18
6 h 0 (0 – 7.2) C 5 (0 – 12) c 0.22
9 h 0 (0 – 5.2) C 6 (0 – 15) c 0.005
12 h 0 (0 – 3) D 1 (0 – 11.2) d 0.08
24 h 0 (0 – 0.3) E 0 (0 – 5) e 0.09
48 h 0 (0 – 2) F 0 (0 – 3.3) f 0.72
Table 1. Pain intensity (median and interquartile range) of the group at the different time assessments along with 
the statistical comparisons.
* Wilcoxon Signed Rank test used for comparisons between groups within each assessment time; ** Friedman 
and Student Neumman ś tests used to compare assessment times within each group. Both groups showed the 
same pattern of statistical differences among assessment times. Similar letters indicate statistically similar means 
within each column.
groups. In the following hours, pain intensity started 
to decrease, but few patients reported pain 48 h after 
the surgery (Table 1). The comparison of both groups 
in each time assessment only showed significant differ-
ences in the 9-h period, with a lower level of pain inten-
sity for group K+T+A than group K.
The mean difference of pain intensity in the different 
assessment periods varied from approximately 4 to 7 
units in a 0 to 100 VAS scale (Table 2).
The need for analgesics in Group K was significantly 
greater than that for Group K+T+A (p < 0.001). How-
ever, the need for antiemetics in Group K+T+A was 
greater than for Group K (p < 0.0001). No differences 
in the median number of pills for both rescue medicines 
(analgesics and antiemetics) were observed between 
groups (p > 0.06) (Table 3). 
The patient’s overall assessment of the surgery in rela-
tion to pain is shown in Table 3. No significant differ-
ences between groups were observed, and most of the 
patients reported that the overall assessment was very 
good and excellent.  
With the exception of three participants, as mentioned 
earlier. No other patient had serious adverse events in 
any of the study groups. However, the total number of 
adverse effects was higher in Group K+T+A (Table 3). 
The most common types of adverse effects are seen in 
Table 4. From all the adverse effects described, dizzi-
ness (p = 0.002), nausea (p = 0.0001) and vomiting (p 
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Time assessment Mean ± SD Mean difference (95% CI)
Group K+T+A Group K
After surgery 0.37 ± 2.4 0.0 ± 0.3 -0.01 (- 0.7 to 0.7)
3 h 11.3 ± 12.6 15.2 ± 16.0 -3.9 (-9.5 to 1.8) 
6 h 6.7 ± 12.4 8.0 ± 9.3 -1.3 (-5.6 to 3.0)
9 h 3.7 ± 6.4 10.8 ± 15.0 -7.1 (-11.7 to -2.5)
12 h 3.3 ± 6.1 6.3 ± 9.3 -3.0 (- 6.1 to 0.1)
24 h 2.6 ± 7.1 5.4 ± 10.8 -2.8 (-6.4 to 0.81)
48 h 4.0 ± 8.7 4.7 ± 9.2 -0.7 (-4.3 to 2.9)
Table 2. Pain intensity (mean ± standard deviations [SD]) of the group at the different time assess-
ments along with effect size. 
Group K+T+A (n = 52) Group K (n = 52) p-value
Need of analgesics N (%) 5 (9.6%) 10 (19%) < 0.001*
Number of pills, mean ± SD, median 
(interquartile range)
0.23 ± 0.78
0 (0 – 0)
0.46 ± 1.16
0 (0 – 0)
0.32**
Need of antiemetic N (%) 16 (30.8%) 0 (0%) < 0.0001*
Number of pills mean ± SD, median 
(interquartile range)
0.32 ± 1.8
0 (0 – 0)
0.0 ± 0.0
0 (0 – 0)
0.06**
Total Adverse effects N (%) 31 (59.6%) 11 (21.1%) < 0.0001*
Global assessment, median (interquartile range) 5 (4 – 5) 4 (4 – 5) 0.185**
Table 3. Comparison of the need of rescue analgesics, antiemetics, total number of adverse effects and global assessment. 
* McNemar ś test; ** Wilcoxon Signed Rank test.
# participants 
with AE in both 
groups
# participants 
without AE in 
both groups
# participants 
with AE only in 
Group K+T+A
# participants 
with AE only in 
Group K
p-value#
Dizziness 1 40 11 0 0.0026
Nausea 1 31 20 0 0.0001
Vomit 1 38 13 0 0.0009
Stomachache or other 
gastrointestinal 
discomforts
0 39 9 4 0.2670
Migraine 0 46 5 1 0.2207
Other effects* 1 41 8* 2** 0.1138
Table 4. Comparison of the number of participants with adverse effects (AE).
#McNemmar’s test; * Loss of appetite (n = 1), Drowsiness (n = 7)*, **Drowsiness (n = 2).
= 0.0009) were statistically more common in Group 
K+T+A than in Group K (Table 4). 
Discussion
Differently than other studies that administered only 
one dose of the medication before (15,16) or after (11) 
surgery, we employed a perioperative protocol in this 
study. A single-dose regimen may provide the fall of 
drug levels in the blood plasma, while a multiple-dos-
age regimen may achieve relatively constant plasma 
concentrations of the drug within the limits of its thera-
peutic window. Considering that the duration of analge-
sia of tramadol/acetaminophen (13) and ketorolac (17) 
was reported to be 5 h and 6 h, respectively, the patients 
were instructed to take the medications every 6 h for 
48 h.
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The strategy of pre-surgical analgesic administra-
tion, as performed in this study (1 h before surgery), 
was used in theory to establish effective blood levels 
for maximum analgesic effect at the time pain is most 
severe. 
Postoperative pain intensity after third molar surgery 
is moderate to severe, usually starts within the first 3 
h and reaches peaks after approximately 6 to 8 h. The 
highest pain levels are recorded within the first 12 h (15, 
18).  From this period on, pain intensity starts to reduce, 
reaching very low levels after 48 h. It is reported that 
this peak of pain, during the early postoperative period, 
coincides with the increased production of biochemical 
mediators of pain at the surgical site (19). 
The worst scenario of pain was detected at the 3-h pe-
riod in the present investigation, with an average pain 
intensity of 15 units in the VAS scale in group K. The 
higher intensity at 3 h compared to the other time assess-
ments may be due to the fact that we used a medium-
duration anesthetic with a 2.5-h duration of analgesia 
(20). Therefore, this period of maximum pain intensity 
coincides with the conclusion of the period of painless-
ness as normal sensations return and when there is an 
increased release of pain mediators (21).
The purpose of using a combination of analgesics with 
different mechanisms of action is to achieve a syner-
gistic potentiation (22), yielding a sufficient analgesic 
effect with lower doses and therefore reducing the in-
tensity and incidence of side effects (23). In this study, 
at the 9-h period, a significant difference was found 
between the groups, with lower pain intensity for the 
group that associated ketorolac with analgesics. The 
synergism that occurs with both drugs that act on dif-
ferent mechanisms of pain perception may adequately 
explain this pain reduction. 
The major mechanism by which ketorolac exerts its 
pharmacological effects is predominantly through the 
peripheral inhibition of prostaglandin synthesis through 
cyclooxygenase-1 and -2 inhibition (24). Ketorolac is 
most active in the periphery and only shows mild cen-
tral nervous system effects at doses far greater than 
those required for analgesic and antiinflammatory ac-
tivity (25). 
Tramadol hydrochloride, which has a weak opioid ac-
tivity, produces analgesia through an opioid effect that 
binds (μ)-opioid receptors and modifies the transmis-
sion of pain signals through the inhibition of serotonin 
and norepinephrine reuptake within pain pathways of 
the central nervous system (13).
Acetaminophen, on the other hand, produces analge-
sia by elevating the pain threshold through inhibition 
of N-methyl D-aspartate or substance P-mediated nitric 
oxide synthesis and/or inhibition of prostaglandin E2 
release in the central nervous system (13). 
The mechanisms responsible for the synergism in the 
analgesic activity of acetaminophen/NSAIDs combina-
tions are not clear. But it seems to involve several mech-
anisms that are probably implicated in the antinocicep-
tive activities, many of them at central levels producing 
a supra-additive or synergic analgesic effect (26). In 
animal models of neuropathic and inflammatory pain, 
there is some evidence for synergistic potentiation be-
tween opioids and NSAIDS (27).
Although lower pain at 9 h was observed for group 
K+T+A, this synergism should be viewed with caution 
because, from a clinical perspective, this difference (or 
effect size) was of a small magnitude and its benefits did 
not overcome the greater number of side effects in the 
combination drug group.
Adverse effects of oral ketorolac were mild in intensity 
and well tolerated, as well as reported by other authors 
(15, 28). Stomachaches or other gastrointestinal discom-
forts, somnolence and migraines were observed in the 
ketorolac group, as previously reported (28). The most 
common adverse effects of tramadol/acetaminophen 
in lower dosages (like the one used in the present in-
vestigation) were nausea, dizziness, vomiting, stomach 
aches or other gastrointestinal discomforts, loss of ap-
petite and somnolence. There were no serious adverse 
events reported for any of the study groups. 
An antiemetic drug (Ondansetron 4 mg) was also used 
as a rescue medication for the control of nausea in pa-
tients. In group K+T+A, 30.8% of the patients took the 
antiemetic, in contrast with only 0% from group K. 
The higher percentage in the association group may be 
justified by the fact that tramadol induces nausea and 
vomiting by stimulation of the chemoreceptor trigger 
zone (CTZ) richly endowed with serotonin receptors. 
Serotonin stimulates the vomiting center and transmits 
signals through the stomach, small intestine, diaphragm 
and abdominal musculature, thus increasing the intra-
gastric pressure that provokes nausea and vomiting.
The need of rescue medication for analgesia (acetamin-
ophen) in the ketorolac group (19%) was significantly 
greater than that observed in the association group 
(9.6%). The associated group required less rescue medi-
cation, probably because of more analgesic potency 
from the basic medication. 
Various factors such as: the preemptive dose, the multi-
ple-dose regimens, the same expert surgeon and surgi-
cal technique for all procedures, the same surgical dif-
ficulty in terms of the magnitude of surgical trauma on 
both sides of the mandible and the similar amount of 
anesthetic volume used in anesthesia techniques might 
in part explain the low amount of analgesics used post-
operatively, compared to single dose regimes (9,15).
The groups presented similar results regarding the over-
all assessment, which can be explained by the overall 
low intensity of pain in both groups. In the worst pain 
situation, where the pain peak occurs, pain intensity 
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ranged from approximately 4-10% of the maximum 
VAS pain. 
We cannot rule out the fact that the use of rescue medica-
tion adds an additional variable to the research design and 
may lead to overestimation of the beneficial effect of the 
group that took more rescue medication. However, with the 
growing rigor of research ethics committees, it is not cur-
rently possible to carry out any research that may submit 
the participants to painful or other types of suffering that 
could be avoided. This also explains why previous clinical 
trials on this issue also employed rescue medication (29). 
Thus, rescue medication is imperative in studies that test 
analgesic control. This was compensated for by comparing 
the amount of rescue medication used in both group.
Conclusions 
Both ketorolac alone and ketorolac plus tramadol/acet-
aminophen showed good control of pain after extraction 
of the lower third molars. Although the VAS score in the 
association group was statistically lower at 9 h, the pain 
difference is small and not clinically relevant, and the as-
sociation is more expensive and caused more side effects.
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